Download presentation
Presentation is loading. Please wait.
Published byColeen Charles Modified over 6 years ago
1
Cell adhesion molecules and insulin-like growth factor-1 in vascular disease
Sandhya K. Balaram, MD, Devendra K. Agrawal, PhD, R.Todd Allen, BA, Charles A. Kuszynski, PhD, John D. Edwards, MD Journal of Vascular Surgery Volume 25, Issue 5, Pages (May 1997) DOI: /S (97) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions
2
Fig. 1 Dose-response effect of IGF-1 on monocyte adherence to HUVECs incubated with various doses of IGF-1 for 4 hours. Values are mean ± SEM. n = 7. *p < 0.01. Journal of Vascular Surgery , DOI: ( /S (97) ) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions
3
Fig. 2 Kinetics of IGF-1-induced increased monocyte adherence to HUVECs. Percent increase over baseline monocyte adherence (in absence of IGF-1) was calculated. Values are mean ± SEM. n = 4. *p < 0.01. Journal of Vascular Surgery , DOI: ( /S (97) ) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions
4
Fig. 3 Effect of IGF-1 in presence and absence of IGF-1 receptor antibody on monocyte adherence to HUVECs. HUVECs were incubated with IGF-1 receptor antibody (dilution 1:50) for 15 minutes before incubation with IGF-1 at 150 ng/ml. Values are mean ± SEM. n = 4. Journal of Vascular Surgery , DOI: ( /S (97) ) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions
5
Fig. 4 Effect of tyrosine kinase inhibitors on IGF-1-induced increased adherence to HUVECs. HUVECs were incubated with genistein (G) 100 μmol/L or herbimycin A (H) μmol/L for 15 minutes before the addition of IGF ng/ml. Values are mean ± SEM. n = 6. *p < 0.01. Journal of Vascular Surgery , DOI: ( /S (97) ) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions
6
Fig. 5 Time course of ICAM-1 expression of HUVECs treated with IGF-1 (150 ng/ml) as detected by immunoblotting with ICAM-1 antibody (dilution 1:1000). T, HUVECs treated with TNF-α (100 U/ml) for 4 hours used as a positive control. B, Baseline untreated HUVECs. Data are representative of three experiments. Journal of Vascular Surgery , DOI: ( /S (97) ) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions
7
Fig. 6 Time course of VCAM-1 expression of HUVECs treated with IGF-1 (150 ng/ml) as detected by immunoblotting with VCAM-1 antibody (dilution 1:1000). B, Baseline untreated HUVECs. Data are representative of three experiments. Journal of Vascular Surgery , DOI: ( /S (97) ) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions
8
Fig. 7 Analysis of surface expression of ICAM-1 (A), VCAM-1 (B), E-selectin (C), and P-selectin (D) on HUVECs incubated with IGF-1 (150 ng/ml) for 4 hours by flow cytometry. X axis represents fluorescence intensity, and Y axis represents relative number of cells. Journal of Vascular Surgery , DOI: ( /S (97) ) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions
9
Fig. 7 Analysis of surface expression of ICAM-1 (A), VCAM-1 (B), E-selectin (C), and P-selectin (D) on HUVECs incubated with IGF-1 (150 ng/ml) for 4 hours by flow cytometry. X axis represents fluorescence intensity, and Y axis represents relative number of cells. Journal of Vascular Surgery , DOI: ( /S (97) ) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions
10
Fig. 7 Analysis of surface expression of ICAM-1 (A), VCAM-1 (B), E-selectin (C), and P-selectin (D) on HUVECs incubated with IGF-1 (150 ng/ml) for 4 hours by flow cytometry. X axis represents fluorescence intensity, and Y axis represents relative number of cells. Journal of Vascular Surgery , DOI: ( /S (97) ) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions
11
Fig. 7 Analysis of surface expression of ICAM-1 (A), VCAM-1 (B), E-selectin (C), and P-selectin (D) on HUVECs incubated with IGF-1 (150 ng/ml) for 4 hours by flow cytometry. X axis represents fluorescence intensity, and Y axis represents relative number of cells. Journal of Vascular Surgery , DOI: ( /S (97) ) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions
12
Fig. 8 Mean fluorescence of ICAM-1 and VCAM-1 expression on HUVECs at various time periods after treatment with IGF-1 (150 ng/ml). Values are mean ± SEM. Data represent three experiments. *p < 0.05. Journal of Vascular Surgery , DOI: ( /S (97) ) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions
13
Fig. 9 Immunoreactivity of representative atherosclerotic aorta specimen stained with the following primary antibodies: Immunoglobulin G isotype control (A), von Willebrand's factor (B), ICAM-1 (C), VCAM-1 (D), E-selectin (E), and P-selectin (F). Specimens were then incubated in biotinylated secondary antibody and stained with immunoperoxidase. Journal of Vascular Surgery , DOI: ( /S (97) ) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions
14
Fig. 9 Immunoreactivity of representative atherosclerotic aorta specimen stained with the following primary antibodies: Immunoglobulin G isotype control (A), von Willebrand's factor (B), ICAM-1 (C), VCAM-1 (D), E-selectin (E), and P-selectin (F). Specimens were then incubated in biotinylated secondary antibody and stained with immunoperoxidase. Journal of Vascular Surgery , DOI: ( /S (97) ) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions
15
Fig. 9 Immunoreactivity of representative atherosclerotic aorta specimen stained with the following primary antibodies: Immunoglobulin G isotype control (A), von Willebrand's factor (B), ICAM-1 (C), VCAM-1 (D), E-selectin (E), and P-selectin (F). Specimens were then incubated in biotinylated secondary antibody and stained with immunoperoxidase. Journal of Vascular Surgery , DOI: ( /S (97) ) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions
16
Fig. 9 Immunoreactivity of representative atherosclerotic aorta specimen stained with the following primary antibodies: Immunoglobulin G isotype control (A), von Willebrand's factor (B), ICAM-1 (C), VCAM-1 (D), E-selectin (E), and P-selectin (F). Specimens were then incubated in biotinylated secondary antibody and stained with immunoperoxidase. Journal of Vascular Surgery , DOI: ( /S (97) ) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions
17
Fig. 9 Immunoreactivity of representative atherosclerotic aorta specimen stained with the following primary antibodies: Immunoglobulin G isotype control (A), von Willebrand's factor (B), ICAM-1 (C), VCAM-1 (D), E-selectin (E), and P-selectin (F). Specimens were then incubated in biotinylated secondary antibody and stained with immunoperoxidase. Journal of Vascular Surgery , DOI: ( /S (97) ) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions
18
Fig. 9 Immunoreactivity of representative atherosclerotic aorta specimen stained with the following primary antibodies: Immunoglobulin G isotype control (A), von Willebrand's factor (B), ICAM-1 (C), VCAM-1 (D), E-selectin (E), and P-selectin (F). Specimens were then incubated in biotinylated secondary antibody and stained with immunoperoxidase. Journal of Vascular Surgery , DOI: ( /S (97) ) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions
19
Fig. 10 Treatment with IGF-1 receptor primary antibody with secondary biotinylated antibody and peroxidase staining of a control aortic specimen (A) and an atherosclerotic aortic specimen (B). Journal of Vascular Surgery , DOI: ( /S (97) ) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions
20
Fig. 10 Treatment with IGF-1 receptor primary antibody with secondary biotinylated antibody and peroxidase staining of a control aortic specimen (A) and an atherosclerotic aortic specimen (B). Journal of Vascular Surgery , DOI: ( /S (97) ) Copyright © 1997 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.